Homologous recombination repair deficiency as a therapeutic target in sarcoma

Area of Science:

• Oncology
• Cancer Biology
• DNA Repair Mechanisms

Background:

• Sarcoma comprises over 50 subtypes, predominantly treated with chemotherapy.
• Understanding sarcoma subtypes is crucial for developing targeted and immunotherapy treatments.
• Homologous recombination (HR) DNA repair pathway defects are known in other cancers, conferring sensitivity to DNA-damaging agents like poly-ADP-ribose polymerase (PARP) inhibitors.

Purpose of the Study:

• To investigate DNA repair defects in sarcoma subtypes.
• To evaluate the therapeutic potential of targeting DNA repair deficiencies in sarcoma.
• To explore the efficacy of PARP inhibitors in combination with DNA-damaging agents in preclinical sarcoma models.

Main Methods:

• Identification of sarcoma subtypes with HR repair pathway defects.
• Preclinical testing of the PARP inhibitor olaparib in combination with the alkylating agent temozolomide.
• Assessment of treatment activity in relevant leiomyosarcoma models.

Main Results:

• Uterine leiomyosarcoma was identified as a subtype with characteristic HR repair pathway defects and frequent BRCA2 loss.
• Preclinical models of leiomyosarcoma demonstrated significant activity when treated with olaparib and temozolomide.
• These findings suggest a potential therapeutic window for PARP inhibitors in specific sarcoma subtypes.

Conclusions:

• Defects in the homologous recombination DNA repair pathway are present in certain sarcoma subtypes, such as uterine leiomyosarcoma.
• Combination therapy with a PARP inhibitor and temozolomide shows marked preclinical activity in leiomyosarcoma.
• Further research may identify additional sarcomas with DNA repair defects, offering new targeted treatment opportunities for rare and aggressive cancers.